TGFβ in T cell biology and tumor immunity: Angel or devil?

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 423-435

  Tu, Eric ^a   Chia, Pei Zhi Cheryl ^a   Chen, Wanjun ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADAPTIVE IMMUNITY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE DYSREGULATION; IMMUNOREGULATION; INDUCED REGULATOY T CELL; INNATE IMMUNITY; INTRINSIC ACTIVITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE; TH17 CELL; TH9 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; IMMUNOLOGY; MACROPHAGE; MOUSE; NEOPLASM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR ESCAPE;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; MACROPHAGES; MICE; MICE, TRANSGENIC; NEOPLASMS; NEUTROPHILS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84907998323     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.014     Document Type: Short Survey

References (215)

1. Schmierer B., Hill C.S. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007, 8:970-982.
2. Mu Y., Gudey S.K., Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012, 347:11-20.
3. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
4. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774.
5. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010, 10:554-567.
6. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Derynck R., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986, 163:1037-1050.
7. Liu Y., Zhang P., Li J., Kulkarni A.B., Perruche S., Chen W. A critical function for TGF-beta signaling in the development of natural CD4+ CD25+ Foxp3+ regulatory T cells. Nat Immunol 2008, 9:632-640.
8. Li M.O., Sanjabi S., Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25:455-471.
9. Marie J.C., Liggitt D., Rudensky A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006, 25:441-454.
10. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
11. Veldhoen M., Hocking R.J., Flavell R.A., Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006, 7:1151-1156.
12. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
13. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
14. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
15. Das J., Ren G., Zhang L., Roberts A.I., Zhao X., Bothwell A.L., et al. Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 2009, 206:2407-2416.
16. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
17. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
18. Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
19. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9:1347-1355.
20. Veldhoen M., Uyttenhove C., van Snick J., Helmby H., Westendorf A., Buer J., et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346.
21. Licona-Limon P., Henao-Mejia J., Temann A.U., Gagliani N., Licona-Limon I., Ishigame H., et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 2013, 39:744-757.
22. Lu Y., Hong S., Li H., Park J., Hong B., Wang L., et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012, 122:4160-4171.
23. Purwar R., Schlapbach C., Xiao S., Kang H.S., Elyaman W., Jiang X., et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012, 18:1248-1253.
24. Yao W., Zhang Y., Jabeen R., Nguyen E.T., Wilkes D.S., Tepper R.S., et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity 2013, 38:360-372.
25. Schmitt E., Germann T., Goedert S., Hoehn P., Huels C., Koelsch S., et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 1994, 153:3989-3996.
26. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
27. Itoh M., Takahashi T., Sakaguchi N., Kuniyasu Y., Shimizu J., Otsuka F., et al. Thymus and autoimmunity: production of CD25+ CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999, 162:5317-5326.
28. Kojima A., Prehn R.T. Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics 1981, 14:15-27.
29. Barrett S.P., Toh B.H., Alderuccio F., van Driel I.R., Gleeson P.A. Organ-specific autoimmunity induced by adult thymectomy and cyclophosphamide-induced lymphopenia. Eur J Immunol 1995, 25:238-244.
30. Marie J.C., Letterio J.J., Gavin M., Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+ CD25+ regulatory T cells. J Exp Med 2005, 201:1061-1067.
31. Ouyang W., Beckett O., Ma Q., Li M.O. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 2010, 32:642-653.
32. Konkel J.E., Jin W., Abbatiello B., Grainger J.R., Chen W. Thymocyte apoptosis drives the intrathymic generation of regulatory T cells. Proc Natl Acad Sci USA 2014, 111:E465-E473.
33. Apostolou I., von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004, 199:1401-1408.
34. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-1227.
35. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+ CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
36. Peng Y., Laouar Y., Li M.O., Green E.A., Flavell R.A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+ CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004, 101:4572-4577.
37. Kasagi S., Zhang P., Che L., Abbatiello B., Maruyama T., Nakatsukasa H., et al. In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response. Sci Transl Med 2014, 6:241ra78.
38. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008, 9:194-202.
39. Maruyama T., Konkel J.E., Zamarron B.F., Chen W. The molecular mechanisms of Foxp3 gene regulation. Semin Immunol 2011, 23:418-423.
40. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
41. Schlenner S.M., Weigmann B., Ruan Q., Chen Y., von Boehmer H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med 2012, 209:1529-1535.
42. Benson M.J., Pino-Lagos K., Rosemblatt M., Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007, 204:1765-1774.
43. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204:1757-1764.
44. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007, 204:1775-1785.
45. Hill J.A., Hall J.A., Sun C.M., Cai Q., Ghyselinck N., Chambon P., et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+ CD44hi cells. Immunity 2008, 29:758-770.
46. Mucida D., Pino-Lagos K., Kim G., Nowak E., Benson M.J., Kronenberg M., et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 2009, 30:471-472. (author reply 2-3).
47. Ishigame H., Zenewicz L.A., Sanjabi S., Licona-Limon P., Nakayama M., Leonard W.J., et al. Excessive Th1 responses due to the absence of TGF-beta signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci USA 2013, 110:6961-6966.
48. Chen W., Jin W., Tian H., Sicurello P., Frank M., Orenstein J.M., et al. Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med 2001, 194:439-453.
49. Konkel J.E., Maruyama T., Carpenter A.C., Xiong Y., Zamarron B.F., Hall B.E., et al. Control of the development of CD8alphaalpha+ intestinal intraepithelial lymphocytes by TGF-beta. Nat Immunol 2011, 12:312-319.
50. Ouyang W., Oh S.A., Ma Q., Bivona M.R., Zhu J., Li M.O. TGF-beta cytokine signaling promotes CD8+ T cell development and low-affinity CD4+ T cell homeostasis by regulation of interleukin-7 receptor alpha expression. Immunity 2013, 39:335-346.
51. Park J.H., Adoro S., Guinter T., Erman B., Alag A.S., Catalfamo M., et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol 2010, 11:257-264.
52. Mucida D., Husain M.M., Muroi S., van Wijk F., Shinnakasu R., Naoe Y., et al. Transcriptional reprogramming of mature CD4(+) helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol 2013, 14:281-289.
53. Doisne J.M., Bartholin L., Yan K.P., Garcia C.N., Duarte N., Le Luduec J.B., et al. iNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med 2009, 206:1365-1378.
54. Havenar-Daughton C., Li S., Benlagha K., Marie J.C. Development and function of murine RORgammat+ iNKT cells are under TGF-beta signaling control. Blood 2012, 119:3486-3494.
55. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
56. McKarns S.C., Schwartz R.H. Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol 2005, 174:2071-2083.
57. Gorelik L., Constant S., Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002, 195:1499-1505.
58. Gorelik L., Fields P.E., Flavell R.A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000, 165:4773-4777.
59. Gorelik L., Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000, 12:171-181.
60. 2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 2003, 197:1689-1699.
61. Reis B.S., Rogoz A., Costa-Pinto F.A., Taniuchi I., Mucida D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity. Nat Immunol 2013, 14:271-280.
62. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
63. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
64. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194:629-644.
65. Chen W., Wahl S.M. TGF-beta: the missing link in CD4+ CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003, 14:85-89.
66. Green E.A., Gorelik L., McGregor C.M., Tran E.H., Flavell R.A. CD4+ CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003, 100:10878-10883.
67. Andersson J., Tran D.Q., Pesu M., Davidson T.S., Ramsey H., O'Shea J.J., et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008, 205:1975-1981.
68. Fahlen L., Read S., Gorelik L., Hurst S.D., Coffman R.L., Flavell R.A., et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005, 201:737-746.
69. Li M.O., Wan Y.Y., Flavell R.A. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26:579-591.
70. Joetham A., Takeda K., Taube C., Miyahara N., Matsubara S., Koya T., et al. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. J Immunol 2007, 178:1433-1442.
71. Read S., Malmstrom V., Powrie F., Cytotoxic T. lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
72. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991, 146:3012-3017.
73. Johns L.D., Flanders K.C., Ranges G.E., Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J Immunol 1991, 147:1792-1796.
74. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
75. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
76. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
77. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
78. Tu E., Bourges D., Gleeson P.A., Ang D.K., van Driel I.R. Pathogenic T cells persist after reversal of autoimmune disease by immunosuppression with regulatory T cells. Eur J Immunol 2013, 43:1286-1296.
79. Chauhan S.K., El Annan J., Ecoiffier T., Goyal S., Zhang Q., Saban D.R., et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 2009, 182:1247-1252.
80. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
81. Gregori S., Giarratana N., Smiroldo S., Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003, 171:4040-4047.
82. Chen W., Frank M.E., Jin W., Wahl S.M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001, 14:715-725.
83. Yang L., Moses H.L. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?. Cancer Res 2008, 68:9107-9111.
84. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
85. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003, 21:21-32.
86. Radoja S., Frey A.B. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med 2000, 6:465-479.
87. Li M.O., Flavell R.A. TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer. Exp Rev Clin Immunol 2006, 2:257-265.
88. Wrzesinski S.H., Wan Y.Y., Flavell R.A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 2007, 13:5262-5270.
89. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
90. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004, 172:7335-7340.
91. Crane C.A., Han S.J., Barry J.J., Ahn B.J., Lanier L.L., Parsa A.T. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology 2010, 12:7-13.
92. Trotta R., Dal Col J., Yu J., Ciarlariello D., Thomas B., Zhang X., et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008, 181:3784-3792.
93. Wahl S.M., Wen J., Moutsopoulos N.M. The kiss of death: interrupted by NK-cell close encounters of another kind. Trends Immunol 2006, 27:161-164.
94. Esendagli G., Bruderek K., Goldmann T., Busche A., Branscheid D., Vollmer E., et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung cancer 2008, 59:32-40.
95. Le Maux Chansac B., Moretta A., Vergnon I., Opolon P., Lecluse Y., Grunenwald D., et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005, 175:5790-5798.
96. Wilson E.B., El-Jawhari J.J., Neilson A.L., Hall G.D., Melcher A.A., Meade J.L., et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PloS One 2011, 6:e22842.
97. Sanjabi S., Mosaheb M.M., Flavell R.A. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009, 31:131-144.
98. Kopp H.G., Placke T., Salih H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009, 69:7775-7783.
99. Laouar Y., Sutterwala F.S., Gorelik L., Flavell R.A. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005, 6:600-607.
100. Banchereau J., Pulendran B., Steinman R., Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?. J Exp Med 2000, 192:F39-F44.
101. Stoitzner P., Green L.K., Jung J.Y., Price K.M., Atarea H., Kivell B., et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol, Immunother: CII 2008, 57:1665-1673.
102. Perrot I., Blanchard D., Freymond N., Isaac S., Guibert B., Pacheco Y., et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007, 178:2763-2769.
103. Gigante M., Blasi A., Loverre A., Mancini V., Battaglia M., Selvaggi F.P., et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2009, 46:893-901.
104. Weber F., Byrne S.N., Le S., Brown D.A., Breit S.N., Scolyer R.A., et al. Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol, Immunother: CII 2005, 54:898-906.
105. Halliday G.M., Le S. Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int Immunol 2001, 13:1147-1154.
106. Ito M., Minamiya Y., Kawai H., Saito S., Saito H., Nakagawa T., et al. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006, 176:5637-5643.
107. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
108. Hubo M., Trinschek B., Kryczanowsky F., Tuettenberg A., Steinbrink K., Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 2013, 4:82.
109. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
110. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+ CD25- T cells into CD4+ CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007, 178:2883-2892.
111. Yamazaki S., Dudziak D., Heidkamp G.F., Fiorese C., Bonito A.J., Inaba K., et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008, 181:6923-6933.
112. Dumitriu I.E., Dunbar D.R., Howie S.E., Sethi T., Gregory C.D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+ CD25+ Foxp3+ regulatory T cells. J Immunol 2009, 182:2795-2807.
113. Zhang X., Huang H., Yuan J., Sun D., Hou W.S., Gordon J., et al. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J Immunol 2005, 175:2931-2937.
114. Roncarolo M.G., Levings M.K., Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001, 193:F5-F9.
115. Gigante M., Mandic M., Wesa A.K., Cavalcanti E., Dambrosio M., Mancini V., et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008, 31:254-262.
116. Ranieri E., Gigante M., Storkus W.J., Gesualdo L. Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007, 147:395-400.
117. Kao J.Y., Gong Y., Chen C.M., Zheng Q.D., Chen J.J. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003, 170:3806-3811.
118. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
119. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
120. Coffelt S.B., Hughes R., Lewis C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009, 1796:11-18.
121. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86:1065-1073.
122. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
123. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
124. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 2010, 185:642-652.
125. Seya T., Akazawa T., Uehori J., Matsumoto M., Azuma I., Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003, 23:4369-4376.
126. Standiford T.J., Kuick R., Bhan U., Chen J., Newstead M., Keshamouni V.G. TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011, 30:2475-2484.
127. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191-202.
128. del Fresno C., Otero K., Gomez-Garcia L., Gonzalez-Leon M.C., Soler-Ranger L., Fuentes-Prior P., et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 2005, 174:3032-3040.
129. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012, 109:6662-6667.
130. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
131. Weiskopf K., Ring A.M., Schnorr P.J., Volkmer J.P., Volkmer A.K., Weissman I.L., et al. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPalpha variants. Oncoimmunology 2013, 2:e25773.
132. Reiter I., Krammer B., Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol 1999, 163:1730-1732.
133. Byrne S.N., Knox M.C., Halliday G.M. TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol 2008, 86:92-97.
134. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795.
135. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489.
136. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
137. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
138. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
139. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
140. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
141. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R., et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109:4336-4342.
142. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol, Immunother: CII 2009, 58:49-59.
143. Ilkovitch D., Lopez D.M. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009, 69:5514-5521.
144. Kusmartsev S., Gabrilovich D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006, 25:323-331.
145. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer J Int cancer 2009, 124:2621-2633.
146. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005, 5:641-654.
147. Corzo C.A., Cotter M.J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009, 182:5693-5701.
148. Donkor M.K., Lahue E., Hoke T.A., Shafer L.R., Coskun U., Solheim J.C., et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 2009, 9:937-948.
149. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010, 70:68-77.
150. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
151. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68:5439-5449.
152. Markowitz J., Wesolowski R., Papenfuss T., Brooks T.R., Carson W.E. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 2013, 140:13-21.
153. Sawant A., Schafer C.C., Jin T.H., Zmijewski J., Tse H.M., Roth J., et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res 2013, 73:6609-6620.
154. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013, 23:200-207.
155. Tecchio C., Scapini P., Pizzolo G., Cassatella M.A. On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 2013, 23:159-170.
156. Dumitru C.A., Gholaman H., Trellakis S., Bruderek K., Dominas N., Gu X., et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer J Int cancer 2011, 129:859-869.
157. Strell C., Lang K., Niggemann B., Zaenker K.S., Entschladen F. Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 2010, 316:138-148.
158. Imai Y., Kubota Y., Yamamoto S., Tsuji K., Shimatani M., Shibatani N., et al. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol 2005, 20:287-293.
159. Shamamian P., Schwartz J.D., Pocock B.J., Monea S., Whiting D., Marcus S.G., et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001, 189:197-206.
160. Caruso R.A., Muda A.O., Bersiga A., Rigoli L., Inferrera C. Morphological evidence of neutrophil-tumor cell phagocytosis (cannibalism) in human gastric adenocarcinomas. Ultrastruct Pathol 2002, 26:315-321.
161. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
162. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol/Hematol 2008, 66:1-9.
163. Reibman J., Meixler S., Lee T.C., Gold L.I., Cronstein B.N., Haines K.A., et al. Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci USA 1991, 88:6805-6809.
164. Smith W.B., Noack L., Khew-Goodall Y., Isenmann S., Vadas M.A., Gamble J.R. Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 1996, 157:360-368.
165. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103:12493-12498.
166. Pekarek L.A., Starr B.A., Toledano A.Y., Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995, 181:435-440.
167. Di Carlo E., Forni G., Lollini P., Colombo M.P., Modesti A., Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
168. Colombo M.P., Lombardi L., Stoppacciaro A., Melani C., Parenza M., Bottazzi B., et al. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. J Immunol 1992, 149:113-119.
169. Scott A.M., Allison J.P., Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immun 2012, 12:14.
170. van Egmond M., Bakema J.E. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol 2013, 23:190-199.
171. Kershaw M.H., Trapani J.A., Smyth M.J. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995, 2:173-181.
172. Schumacher K., Haensch W., Roefzaad C., Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61:3932-3936.
173. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001, 61:5132-5136.
174. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl J Med 2003, 348:203-213.
175. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol: Off J Am Soc Clin Oncol 2007, 25:2586-2593.
176. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
177. Donkor M.K., Sarkar A., Savage P.A., Franklin R.A., Johnson L.K., Jungbluth A.A., et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011, 35:123-134.
178. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001, 7:1118-1122.
179. Hinrichs C.S., Kaiser A., Paulos C.M., Cassard L., Sanchez-Perez L., Heemskerk B., et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009, 114:596-599.
180. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
181. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207:637-650.
182. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003, 197:1017-1028.
183. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
184. Girardi M., Oppenheim D., Glusac E.J., Filler R., Balmain A., Tigelaar R.E., et al. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol 2004, 122:699-706.
185. Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L.A., Chu N.R., et al. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 2005, 65:2018-2025.
186. Perez-Diez A., Joncker N.T., Choi K., Chan W.F., Anderson C.C., Lantz O., et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
187. Gao F.G., Khammanivong V., Liu W.J., Leggatt G.R., Frazer I.H., Fernando G.J. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 2002, 62:6438-6441.
188. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
189. Lai Y.P., Lin C.C., Liao W.J., Tang C.Y., Chen S.C. CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses. PloS One 2009, 4:e7766.
190. Lowes M.A., Bishop G.A., Crotty K., Barnetson R.S., Halliday G.M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997, 108:914-919.
191. Fridman W.H. The immune microenvironment as a guide for cancer therapies. Oncoimmunology 2012, 1:261-262.
192. Maeda H., Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996, 156:73-78.
193. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol, Immunother: CII 2005, 54:721-728.
194. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009, 21:200-208.
195. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
196. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 2008, 105:15505-15510.
197. Zhang B., Rong G., Wei H., Zhang M., Bi J., Ma L., et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008, 374:533-537.
198. Martin-Orozco N., Chung Y., Chang S.H., Wang Y.H., Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009, 39:216-224.
199. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
200. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7:651-658.
201. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer J Int cancer 2010, 127:759-767.
202. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
203. Hindley J.P., Ferreira C., Jones E., Lauder S.N., Ladell K., Wynn K.K., et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011, 71:736-746.
204. Strauss L., Whiteside T.L., Knights A., Bergmann C., Knuth A., Zippelius A. Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007, 178:320-329.
205. Valzasina B., Piconese S., Guiducci C., Colombo M.P. Tumor-induced expansion of regulatory T cells by conversion of CD4+ CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006, 66:4488-4495.
206. Gomella L.G., Sargent E.R., Linehan W.M., Kasid A. Transforming growth factor-beta inhibits the growth of renal cell carcinoma in vitro. J Urol 1989, 141:1240-1244.
207. Zhou G., Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007, 178:2155-2162.
208. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
209. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001, 182:207-214.
210. Whiteside T.L., Schuler P., Schilling B. Induced and natural regulatory T cells in human cancer. Exp Opin Biol Ther 2012, 12:1383-1397.
211. Bergmann C., Strauss L., Wang Y., Szczepanski M.J., Lang S., Johnson J.T., et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res: Off J Am Assoc Cancer Res 2008, 14:3706-3715.
212. Akasaki Y., Liu G., Chung N.H., Ehtesham M., Black K.L., Yu J.S. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004, 173:4352-4359.
213. Dobrzanski M.J., Rewers-Felkins K.A., Samad K.A., Quinlin I.S., Phillips C.A., Robinson W., et al. Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol, Immunother: CII 2012, 61:839-854.
214. Segal B.M., Glass D.D., Shevach E.M., Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002, 168:1-4.
215. Connolly E.C., Saunier E.F., Quigley D., Luu M.T., De Sapio A., Hann B., et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res 2011, 71:2339-2349.